As part of its effort to enter the fast-growing and high-potential Scar Management segment, Glenmark has in-licensed its first product for the Indian market. The company entered into a strategic in-licensing agreement with the Swiss firm, Stratpharma to market and distribute Strataderm in India.

AS Mohanty, director of formulations, said: “The scar management segment has, so far, not been a focus area for pharmaceutical companies and we are glad to make an entry into this segment with a product that could be used on scars caused due to a variety of reasons.

“This is our first in-licensed product for the Indian market and we will continue to pursue in-licensing opportunities to bridge product gaps in operating therapy areas as well as in-license differentiated products to strengthen our product portfolio. We will continue to look for more in-licensing opportunities in the dermatology segment to strengthen our leadership position in this area.”

Strataderm was developed for use on all types of scars including those resulting from general surgery, trauma, chronic wounds, burns, bites, acne and other diseases of the skin. It can be used on old or new scars, once the wound is healed (Epithelialized). Strataderm is ideal for people with sensitive skin and for children, said the company.

The product has been developed using a new silicone polymer technology that is self drying without the use of Silicone Dioxide. The product will be available in a gel formulation in a 10g tube.

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. It employs over 4100 people across its global operations and its shares are listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

You can learn more about Strataderm on, follow us on Facebook or Twitter.